Institute for Quality and Efficiency in Health Care

Added benefit of lisdexamfetamine is not proven

Lisdexamfetamine dimesylate (trade name: Elvanse) has been approved in Germany since March 2013 as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and ...

Sep 03, 2013
popularity not rated yet | comments 0

Benefit of PET or PET/CT in oesophageal cancer is not proven

The patient-relevant benefit of positron emission tomography (PET) in oesophageal cancer, alone or in combination with computed tomography (CT), is not proven due to a lack of comparative studies. In terms of their diagnostic ...

Aug 28, 2013
popularity not rated yet | comments 0

Vandetanib in thyroid cancer: Added benefit not proven

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute ...

Aug 02, 2013
popularity not rated yet | comments 0

Added benefit of lixisenatide is not proven

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together ...

Aug 02, 2013
popularity not rated yet | comments 0

Abiraterone: Hint of considerable added benefit

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms ...

Jul 02, 2013
popularity not rated yet | comments 0